Office of the Registrar or Lobbying of BC

Menus

  • Menus

www.lobbyistsregistrar.bc.ca

  • www.lobbyistsregistrar.bc.ca

Designated Filer menu

  • Registry Search Tools
    • 12-Month Lobbying Activity Search
    • Advanced Registry Search
  • Reporting Tools
    • Recent Registrations
    • Recent Lobbying Activity Reports by Posted Date
    • Government Funding Report
    • Gifts to Public Office Holders Report
    • Listing of All Lobbyists and Senior Officers
    • Listing of Senior Public Officer Holders who are in Lobbying Activity Reports
    • Listing of Organizations Clients and their Direct Interests
  • Lobbying Statistics
    • Active Lobbyists and Registrations by Type
    • Ministries/Provincial Entities in Active Registrations
    • Ministries/Provincial Entities in Lobbying Activity Reports
    • Lobbying Activity Reports by Reporting Period
    • Subject Matter in Active Registrations
    • Subject Matter in Lobbying Activity Reports
    • Intended Outcomes in Active Registrations
    • Intended Outcomes in Lobbying Activity Reports
  • Help
    • LTA Guidance Documents
    • Using the Registry
    • Legislation
    • LTA Frequently Asked Questions
    • Contact Us
  • Sign In

You are here:

  1. Registry Dashboard

 

Subject Matter Details

Subject Matter of the Lobbying Activities
Details Regarding the Identified Subject Matter
Details Regarding the Identified Subject Matter
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Arranging a meeting between the CGPA and Ministerial Staff to provide a briefing on generic and biosimilars sectors and pan-Canadian Pharmaceutical Alliance agreement.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Policy and timing in respect of listing of sole-source and other generic drugs on the PharmaCare formulary where the price offered is higher than the Province's desired price. BC's position in respect of administration of pan-Canadian Pharmaceutical Association arrangements with the CGPA regarding generic drugs. Curtailing use of coupon cards for pharmaceutical products. Development of a regulatory pathway for biosimiars. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Promoting greater utilization of generic prescription medicines. BC's position in respect of the National Pharmacare initiative. Accelerating time for listing of generic drugs after submission.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health